New Cryopreservation Technology of hMSCs: First Preclinical Results Using DMSO-containing Medium
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články
PubMed
33973985
Knihovny.cz E-zdroje
- MeSH
- dimethylsulfoxid * farmakologie MeSH
- klinické zkoušky jako téma MeSH
- kryoprezervace MeSH
- kryoprotektivní látky farmakologie MeSH
- lidé MeSH
- mezenchymální kmenové buňky * MeSH
- průtoková cytometrie MeSH
- technologie MeSH
- viabilita buněk MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- dimethylsulfoxid * MeSH
- kryoprotektivní látky MeSH
BACKGROUND: Human mesenchymal stem cells (hMSCs) have tremendous potential in regenerative medicine, making it desirable to cryopreserve and bank them to increase their access and availability. OBJECTIVE: This research is part of a clinical trial performed on six patients that aimed to use advanced therapy medicinal products (ATMPs) based on hMSCs in patients undergoing repeated total hip replacement. MATERIALS AND METHODS: To compare the characteristics of fresh and frozen hMSCs, we used the trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determinations and the clonogenic assay of cell proliferation. RESULTS: Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs in suspension. When using a medium containing dimethyl sulfoxide (DMSO), the viability was higher than 90% in all cases. The cell purity determined by flow cytometry was also acceptable. CONCLUSION: These initial results show that the prepared cryopreserved ATMP exhibited good viability and phenotype characteristics.
Bioinova Ltd Prague Czech Republic
Faculty of Military Medicine of the University of Defence in Hradec Kralove Czech Republic
Tissue Bank University Hospital Hradec Kralove Hradec Kralove Czech Republic
